Human Primary Diabetic Vein Smooth Muscle Cells
Quick Actions
Product Data Sheet
Technical Documentation
Download detailed specifications, protocols, and safety information
File size: 175.1 KB
Product Overview
Description
Human Primary Diabetic Vein Smooth Muscle Cells are a specialized type of cell line derived from human veins affected by diabetes. These cells exhibit unique characteristics that reflect the physiological and pathological conditions associated with diabetes, particularly in relation to vascular health. They are essential for studying the effects of diabetes on vascular smooth muscle function, signaling pathways, and potential therapeutic interventions aimed at improving cardiovascular outcomes in diabetic patients.
Guarantee expansion for a minimum of 2-5 population
doublings.
IMPORTANT: Quality warranty requires use of NeoBioPharma media. Biohazardous material despite negative pathogen testing. Quality claims must be reported within 1 month.
Key Features
Catalog Number: NBPDS013
Product Format: Frozen
Vial Cell Number: > 5x10[5] cells/vial
Passage:1(P1)
Storage: Liquid Nitrogen, Vapor Phase
Intended Use: Research use only (RUO)
Characterization Markers
Characterized by positive expression of smooth muscle cell-specific alpha-actin.
Quick Facts
Product Type
Human Type II Diabetes Endothelial Cells
Viability
>95% viable (Trypan Blue exclusion)
Applications
Restenosis and Vein Graft Failure: Diabetic patie…
Availability
In Stock • Global Shipping
Technical Specifications
Primary Applications
Applications & Use Cases
Primary Applications
Restenosis and Vein Graft Failure: Diabetic patients have significantly higher rates of vein graft occlusion after bypass surgery. Researchers use these cells to test drugs (e.g.
Suitable for restenosis and vein graft failure: diabetic patients have significantly higher rates of vein graft occlusion after bypass surgery. researchers use these cells to test drugs (e.g. studies and research applications
mTOR inhibitors
Suitable for mtor inhibitors studies and research applications
anti-proliferatives) that might prevent the excessive smooth muscle cell proliferation that closes off the graft. Diabetic Vasculopathy: Understanding why diabetic patients suffer from accelerated atherosclerosis and peripheral artery disease (PAD) involving the venous system. Wound Healing: Venous insufficiency is a major cause of diabetic foot ulcers. Studying the contractility and migration of these cells helps understand why wound contraction fails in diabetic patients. Drug Screening: Pharmaceutical companies use these primary cells to test the vascular toxicity or efficacy of new antidiabetic drugs
Suitable for anti-proliferatives) that might prevent the excessive smooth muscle cell proliferation that closes off the graft. diabetic vasculopathy: understanding why diabetic patients suffer from accelerated atherosclerosis and peripheral artery disease (pad) involving the venous system. wound healing: venous insufficiency is a major cause of diabetic foot ulcers. studying the contractility and migration of these cells helps understand why wound contraction fails in diabetic patients. drug screening: pharmaceutical companies use these primary cells to test the vascular toxicity or efficacy of new antidiabetic drugs studies and research applications
ensuring that therapies intended to lower glucose do not inadvertently cause vascular smooth muscle proliferation.
Suitable for ensuring that therapies intended to lower glucose do not inadvertently cause vascular smooth muscle proliferation. studies and research applications
Research Areas
In Vitro Studies
Cell culture and screening applications
Molecular Biology
Gene expression & signaling studies
Drug Discovery
Screening & validation studies
Disease Modeling
Pathophysiology research
Support & Resources
Technical Support
Our experts are available for technical questions and protocol assistance.
Contact Support
